Strategy of radiotherapy for oligometastasis from colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2016.02.05

Abstract

Abstract:

Oligometastasis from colorectal cancer is one of the important fields of current research. Clinical trials of stereotactic body radiotherapy for liver, lung or multi-organ metastasis are gradually developed. There has been an international MDT consensus on recommendation of pelvic irradiation for patients with oligometastasis from rectal cancer.

Key words: Colorectal neoplasms, Neoplasm metastasis, Stereotactic body radiotherapy, Pelvic irradiation

Hua Ren, Jing Jin. Strategy of radiotherapy for oligometastasis from colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(02): 133-137.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.02.05

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I02/133

Figures/Tables 1

References 32

[1]	Hellman S, Weichselbaum R. Oligometastases. J Clin Oncol, 1995, 13(1): 8-10.
[2]	Nordlinger B, Sorbye H, Glimelius B,et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol, 2013, 14(12): 1208-1215.
[3]	Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol, 2012, 23(10): 2619-2626.
[4]	Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013, 24(Suppl 6): vi81-88.
[5]	Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol, 1995, 34(6): 861-870.
[6]	Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys, 2012, 82(3): 1047-1057.
[7]	Chang DT, Swaminath A, Kozak M, et al. Sterotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer, 2011, 117(17): 4060-4069.
[8]	Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol, 2011, 18(4): 1081-1087.
[9]	Robertson JM, Lawrence TS, Walker S, et al. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Radiat Oncol Biol Phys, 1995, 32(2): 445-450.
[10]	Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol, 2000, 18(11): 2210-2218.
[11]	Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol, 2005, 23(34): 8739-8747.
[12]	Ohri N, Jackson A, Mendes Romeo A, et al. Local control following stereotactic body radiotherapy for liver tumor: a preliminary report of the AAPM working group for SBRT. Int J Radiat Oncol Biol Phys, 2014, 50 (supplement): S52. ABSTRCT 106.
[13]	Liu E, Stenmark MH, Lee OE, et al. SBRT as an alternative to RFA for the treatment of primary and metastatic liver tumors. Journal of Clinical Oncology, 2012 Gastrointestinal Cancers Symposium. 2012, 30: No 4suppl (February 1 Supplement), ABSTRCT 158.
[14]	梁建伟，周志祥，刘骞，等．可切除结直肠癌肺转移的预后因素分析．中华肿瘤杂志，2010，32(9): 694-697.
[15]	Sternberg DI, Sonett JR. Surgical therapy of lung metastases. Semin Oncol. 2007, 34(3): 186-196.
[16]	Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol, 2015, 16(6):630-637.
[17]	Salama JK, Kirkpatrick J, Yin FF. Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol, 2012, 9(11): 654-665.
[18]	Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol, 2009, 27(10): 1572-1578.
[19]	Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1516-1522.
[20]	Gunjur A, Duong C, Ball D, et al. Surgical and ablative therapies for the management of adrenal ′oligometastases′ - A systematic review. Cancer Treat Rev. 2014, 40(7): 838-846.
[21]	Pastorino U, Buyse M, Friedel G, et al. The International Registry of Lung Metastases: Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg, 1997, 113(1): 37-49.
[22]	Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys, 2005, 62(5): 1371-1378.
[23]	Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol, 2009, 27(10): 1572-1578.
[24]	Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): s94-s100.
[25]	Assumpcao L, Choti MA, Gleisner AL, et al. Patterns of recurrence following liver resection for colorectal metastases. Arch Surg, 2008, 143(8): 743-749.
[26]	Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer, 2012, 118(21): 5414-5423.
[27]	Logan JK, Huber KE, Dipetrillo TA, et al. Patterns of care of radiation therapy in patients with stage IV rectal cancer: a Surveillance, Epidemiology, and End Results analysis of patients from 2004 to 2009. Cancer, 2014, 120(5): 731-737.
[28]	Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg, 2010, 97(7): 580-587.
[29]	Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, et al. Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol, 2013, 107(2): 171-177.
[30]	Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer, 2013, 13: 279.
[31]	Van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol, 2013, 24(7): 1762-1769.
[32]	Tyc-Szczepaniak D, Wyrwicz L, Kepka L, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol, 2013, 24(11): 2829-2834.

器官	体积	体积剂量（Gy）	限量依据
肺	<1500 cc	12.5	RTOG 0813
肺	<1000 cc	13.5	RTOG 0813
肝	<700 cc	21.0	Timmerman
肾（同侧）	<130 cc	14.5	Timmerman
十二指肠	<0.5 cc	30.0	RTOG 1112
脊髓	<0.35 cc	22.0	Timmerman
脊髓	<1.2 cc	15.6	Timmerman
脑	5~10 cc	12.0	QUANTEC (radiosurgery)

器官	体积	体积剂量（Gy）	限量依据
肺	<1500 cc	12.5	RTOG 0813
肺	<1000 cc	13.5	RTOG 0813
肝	<700 cc	21.0	Timmerman
肾（同侧）	<130 cc	14.5	Timmerman
十二指肠	<0.5 cc	30.0	RTOG 1112
脊髓	<0.35 cc	22.0	Timmerman
脊髓	<1.2 cc	15.6	Timmerman
脑	5~10 cc	12.0	QUANTEC (radiosurgery)

Please choose a citation manager

Content to export